Moteur de recherche d’entreprises européennes
Financement de l’UE (18,2 M €) : Centre européen de dépistage ; Une bibliothèque unique pour une biologie attrayante Hor 01/12/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Centre européen de dépistage ; Une bibliothèque unique pour une biologie attrayante
By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner). ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.
| Astrazeneca AB | 0,00 € |
| Bayer AG | 0,00 € |
| Bioascent Discovery Ltd. | 6 475 450 € |
| Edelris SAS | 292 600 € |
| Grunenthal GmbH | 0,00 € |
| Institut de Recherches Servier | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| Merck KGaA | 0,00 € |
| MMV Medicines FOR Malaria Venture | 0,00 € |
| Pivot Park Screening Centre B.V. | 7 128 756 € |
| Sanofi-Aventis Deutschland GmbH | 0,00 € |
| Stichting Lygature | 1 434 944 € |
| Sygnature Discovery Ltd. | 292 600 € |
| Symeres Netherlands B.V. | 585 200 € |
| Taros Chemicals GmbH & Co. KG | 292 600 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 491 230 € |
| UCB Biopharma | 0,00 € |
| University of Dundee | 1 256 613 € |
https://cordis.europa.eu/project/id/806948
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.